Sanara MedTech (SMTI) EBIT (2010 - 2026)

Sanara MedTech's EBIT history runs 16 years deep, the most recent figure standing at $2.6 million for Q1 2026.

• Quarterly EBIT rose 220.59% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.6 million (up 574.43% YoY) and the FY2025 annual result came in at $7.3 million, up 480.26% from the prior year.
• EBIT was $2.6 million for Q1 2026 at Sanara MedTech, up from $1.1 million in the prior quarter.
• Across five years, EBIT topped out at $2.9 million in Q3 2025 and bottomed at -$3.4 million in Q2 2022.
• A 5-year average of -$628086.9 and a median of -$906655.0 in 2023 frame the typical range for EBIT.
• Annual changes were most pronounced in 2022 — EBIT slumped 229.86% — and 2024, when it soared 1100.21%.
• Sanara MedTech's EBIT stood at -$3.1 million in 2022, then surged by 92.76% to -$225995.0 in 2023, then surged by 1100.21% to $2.3 million in 2024, then tumbled by 53.53% to $1.1 million in 2025, then surged by 151.95% to $2.6 million in 2026.
• Business Quant data shows SMTI's EBIT at $2.6 million in Q1 2026, $1.1 million in Q4 2025, and $2.9 million in Q3 2025.